Moderna Beats Profit Estimates, Fueled by Covid-19 Vaccine Sales

Moderna Inc. posted better-than-expected profits for the last three months of 2021 as the company’s Covid-19 vaccine continued to power its year-over-year growth, while executives mulled plans to roll out an additional booster shot. In the latest quarter, Moderna’s revenue reached $7.21 billion, with nearly all of that coming from vaccine sales. The Cambridge, Mass., company said it distributed a total of 807 million doses of the vaccine, Spikevax, last year. For all of 2021, Moderna posted revenue of $18.5 billion, nearly all of it from Covid-19 vaccine sales. That figure could rise this year: The company said it has signed advanced purchase agreements from national governments to supply $19 billion worth of vaccines for full-year 2022, with options for more.